AIM ImmunoTech (UK) Insiders
| 0A4Y Stock | 0.20 0.01 4.76% |
AIM ImmunoTech employs about 26 people. The company is managed by 9 executives with a total tenure of roughly 61 years, averaging almost 6.0 years of service per executive, having 2.89 employees per reported executive. Breaking down AIM ImmunoTech's management performance can provide insight into the firm performance.
| Esq JD Chairman CEO Chairman |
AIM |
AIM ImmunoTech Management Team Effectiveness
The company has return on total asset (ROA) of (0.8004) % which means that it has lost $0.8004 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5479) %, meaning that it generated substantial loss on money invested by shareholders. AIM ImmunoTech's management efficiency ratios could be used to measure how well AIM ImmunoTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AIM ImmunoTech's Total Assets are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 60.6 M in 2025, whereas Other Current Assets are likely to drop slightly above 611.2 K in 2025.Net Loss is likely to drop to about (18.1 M) in 2025
AIM ImmunoTech Workforce Comparison
AIM ImmunoTech is number one stock in number of employees category among its peers. The total workforce of Energy industry is presently estimated at about 196,380. AIM ImmunoTech adds roughly 26.0 in number of employees claiming only tiny portion of equities under Energy industry.
AIM ImmunoTech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. AIM ImmunoTech Price Series Summation is a cross summation of AIM ImmunoTech price series and its benchmark/peer.
AIM ImmunoTech Notable Stakeholders
An AIM ImmunoTech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AIM ImmunoTech often face trade-offs trying to please all of them. AIM ImmunoTech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AIM ImmunoTech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Esq JD | CEO Chairman | Profile | |
| III Esq | Exec COO | Profile | |
| Ann Coverly | Director Coordinator | Profile | |
| Jodie Pelz | Director Finance | Profile | |
| David MD | Chief Director | Profile | |
| MBA IV | Chief Officer | Profile | |
| Christopher McAleer | Scientific Officer | Profile | |
| Ralph Cavalli | Vice Manufacturing | Profile | |
| Carol Smith | Chief Officer | Profile |
About AIM ImmunoTech Management Performance
The success or failure of an entity such as AIM ImmunoTech often depends on how effective the management is. AIM ImmunoTech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AIM management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AIM management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AIM ImmunoTech is entity of United Kingdom. It is traded as Stock on LSE exchange.
Please note, the imprecision that can be found in AIM ImmunoTech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AIM ImmunoTech. Check AIM ImmunoTech's Beneish M Score to see the likelihood of AIM ImmunoTech's management manipulating its earnings.
AIM ImmunoTech Workforce Analysis
Traditionally, organizations such as AIM ImmunoTech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AIM ImmunoTech within its industry.AIM ImmunoTech Manpower Efficiency
Return on AIM ImmunoTech Manpower
| Revenue Per Employee | 7.7K | |
| Revenue Per Executive | 22.3K | |
| Net Loss Per Employee | 747.9K | |
| Net Loss Per Executive | 2.2M |
Additional Tools for AIM Stock Analysis
When running AIM ImmunoTech's price analysis, check to measure AIM ImmunoTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AIM ImmunoTech is operating at the current time. Most of AIM ImmunoTech's value examination focuses on studying past and present price action to predict the probability of AIM ImmunoTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AIM ImmunoTech's price. Additionally, you may evaluate how the addition of AIM ImmunoTech to your portfolios can decrease your overall portfolio volatility.